PURPOSE: An apoptosis inhibitor 5 (API5) gene is provided to be used as a pathological marker for diagnosing, suppressing, and reducing cancer with immune escape and to screen a cancer therapeutic agent.CONSTITUTION: A composition for preventing or treating cancer with immune escape contains an inhibitor of one or more genes selected among API5, protein kinase C delta (PKC delta), extracellular signal-regulated kinase (ERK), signal transducer and activator of transcription 3 ( STAT3), and interleukin-6 (IL-6). The inhibitor is siRNA, antisense-oligonucleotide, shRNAi, miRNA, or a vector containing the same. siRNA is selected among sequence numbers 3, 5, 7, 9, and 11. A method for screening a medicine for preventing or treating cancer with immune escape comprises the steps of: making a candidate material and one or more genes selected among API5, PKC delta, ERK, STAT3, and IL-6 come in contact in vitro and determining if the candidate material promotes or suppresses the expression of the genes.COPYRIGHT KIPO 2013[Reference numerals] (AA) Immunosuppression (BB) Protoplasm (CC) Generating IL-6 (DD) Activating caspase-3 (EE) Cell death (FF) BIM decomposition (GG) Nucleus본 발명은 항암면역우회암의 표시인자 및 항암치료내성 무력화 표적으로서 API5의 용도에 관한 것으로, 보다 상세하게는, 항암면역우회암을 진단하는 병리적 마커로 API5 유전자와 이에 신호 전달 경로 관련 인자들을 표적화하거나 활성을 저해함으로써 API5에 의한 항암면역내성 및 항암면역억제를 무력화할 뿐만 아니라, 병행되는 항암치료의 치료적 효과를 높일 수 있다.
